Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in upper limb essential tremor
NCT05216250Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2022
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of botulinum toxin in essential tremor (ET), sponsored by AbbVie Inc.. Started Apr 2022; status: completed.
02
Drugs
botulinum toxin
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT05216250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216250.